Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Sort descending Date Recommendation Issued
Forteo Teriparatide (rDNA origin) injection Osteoporosis Do not list Complete
Ciprodex Ciprofloxacin hydrochloride and dexamethasone otic suspension Otitis media with otorrhea & otitis externa, acute Do not list Complete
Gynazole.1 Butoconazole nitrate Vaginal infection Do not list Complete
Teveten Plus Eprosartan mesylate/ hydrochlorothiazide Hypertension, Essential List in a similar manner to other drugs in class Complete
Remodulin Treprostinil sodium Pulmonary arterial hypertension (NYHA Class III and IV patients) Do not list Complete
Sensipar Cinacalcet hydrochloride Secondary hyper-parathyroidism in chronic kidney disease Do not list Complete
Avodart Dutasteride Prostatic hyperplasia, benign List in a similar manner to other drugs in class Complete
VFEND Voriconazole Aspergillosis, Invasive Withdrawn
Relpax Eletriptan hydrobromide Migraine Do not list Complete
Humira Adalimumab Arthritis, Rheumatoid List with clinical criteria and/or conditions Complete